Last updated: April 25, 2026
What is “IS8052” and what does the patent cover?
IS8052 is recorded as an Iceland-issued patent connected to a specific drug product. However, no structured bibliographic record (publication number, applicant, title, IPC/CPC, priority dates, or linked family documents) is present in the information available in this conversation. With no authoritative registry entry, claims text, or even the underlying active ingredient linked to “IS8052,” a complete and accurate scope-and-claims analysis cannot be produced.
What are the claim boundaries in IS8052?
A claim boundary analysis requires the exact independent claim(s) and claim set (including method-of-treatment, product, use, dosage, and composition sub-claims), plus the enabling description terms used to limit scope (for example, definitions of chemical entities, salts/polymorphs, formulations, and patient populations). Those claim texts are not available here. Without the claims, any attempt to map scope would risk inaccuracy.
What does the patent landscape look like around IS8052?
A landscape view requires:
- Identification of the drug substance (INN/chemical name) and the specific invention in IS8052 (compound vs formulation vs use).
- Retrieval of global family members (EPO/WO/US/CN/JP, etc.).
- Mapping of regulatory relevance (marketing authorization and exclusivity status, if applicable).
- Claim charting against likely design-arounds and generics/biosimilars.
None of those inputs are available in the provided material. As a result, no accurate landscape can be generated.
Key Takeaways
- IS8052 cannot be analyzed for scope or claims with the information currently available in this session.
- A defensible patent landscape cannot be produced without the linked drug identity and the underlying bibliographic record and claim text.
- No reliable determination of claim breadth, inventive concept, or likely infringement/design-around risk can be made.
FAQs
1) Is IS8052 a product, method, or formulation patent?
Not determinable from the provided information.
2) What active ingredient or therapeutic area does IS8052 cover?
Not determinable from the provided information.
3) Does IS8052 belong to a larger global patent family?
Not determinable from the provided information.
4) Are there known opposition, litigation, or grant/validity events tied to IS8052?
Not determinable from the provided information.
5) What would be the fastest way to assess design-around risk from IS8052?
Claim text and family documents are required, but they are not available in this session.
References
[1]
